DreamPirates DreamPirates

After Early Hopes AstraZeneca-Oxford Vaccine Suffer Setbacks

Author : lahoregreenz
Publish Date : 2021-02-09 12:17:45
After Early Hopes AstraZeneca-Oxford Vaccine Suffer Setbacks

London: The coronavirus vaccine developed in Britain by Oxford University and UK-Swedish pharmaceutical firm AstraZeneca has suffered several setbacks since its development, dampening hopes over its global role in ending the pandemic. Doubts have been heightened after South Africa suspended the start of its inoculation programme using the jab this week, following research it had failed to prevent mild and moderate cases of a virus variant there. The shot was already under scrutiny about its efficacy for over-65s, after several European countries restricted its use to younger adults only, despite approval from the EU medicines agency for all ages. In a sign of the mixed-messaging, French President Emmanuel Macron said at the end of January the vaccine was "quasi-ineffective for people over 65". Many poorer nations around the world are relying on the logistical advantages offered by the AstraZeneca-Oxford vaccine, which does not require ultra-low storage conditions. In Britain, where more than 12 million jabs have been given as part of the country's biggest ever vaccination drive, it has been administered alongside the Pfizer-BioNTech shot. Prime Minister Boris Johnson on Monday sought to reassure the millions of Britons already given the AstraZeneca-Oxford vaccine, telling reporters UK officials believe both jabs were "effective in combating serious disease and death against all variants". Scientists were getting "ever faster and more expert" to come up with "variants of the vaccines" to adapt to the evolving situation, he added. 'Minimal protection' The University of Witwatersrand, Johannesburg, which conducted the trial that has prompted the latest concerns, reported Sunday that it only "provides minimal protection against mild-moderate Covid-19 infection" from the South African variant. However, AstraZeneca noted none of the 2,000 participants developed serious symptoms and reiterated its belief that the vaccine will still protect against severe disease. Peter English, a former head of the British Medical Association's public health medicine committee, agreed "what matters most is preventing more serious forms of Covid-19" and that more extensive trials involving the South African strain were still needed. "It is by no means clear if it is more or less effective against the variant than other vaccines," he added. In Britain, Oxford University said Friday researchers had found its jab had "similar efficacy" against a more contagious variant that first emerged in September and has become the dominant form of coronavirus across the country. The news was welcomed in Britain, where some 113,000 people have died during the pandemic, and where vaccines are seen as a way out of the crisis. "We are ready to protect our most vulnerable and stay a step ahead of the virus, whatever it throws at us," vaccines minister Nadhim Zahawi wrote Monday in the Daily Telegraph.

London: The coronavirus vaccine developed in Britain by Oxford University and UK-Swedish pharmaceutical firm AstraZeneca has suffered several setbacks since its development, dampening hopes over its global role in ending the pandemic. Doubts have been heightened after South Africa suspended the start of its inoculation programme using the jab this week, following research it had failed to prevent mild and moderate cases of a virus variant there. The shot was already under scrutiny about its efficacy for over-65s, after several European countries restricted its use to younger adults only, despite approval from the EU medicines agency for all ages. In a sign of the mixed-messaging, French President Emmanuel Macron said at the end of January the vaccine was "quasi-ineffective for people over 65". Many poorer nations around the world are relying on the logistical advantages offered by the AstraZeneca-Oxford vaccine, which does not require ultra-low storage conditions. In Britain, where more than 12 million jabs have been given as part of the country's biggest ever vaccination drive, it has been administered alongside the Pfizer-BioNTech shot. Prime Minister Boris Johnson on Monday sought to reassure the millions of Britons already given the AstraZeneca-Oxford vaccine, telling reporters UK officials believe both jabs were "effective in combating serious disease and death against all variants". Scientists were getting "ever faster and more expert" to come up with "variants of the vaccines" to adapt to the evolving situation, he added. 'Minimal protection' The University of Witwatersrand, Johannesburg, which conducted the trial that has prompted the latest concerns, reported Sunday that it only "provides minimal protection against mild-moderate Covid-19 infection" from the South African variant. However, AstraZeneca noted none of the 2,000 participants developed serious symptoms and reiterated its belief that the vaccine will still protect against severe disease. Peter English, a former head of the British Medical Association's public health medicine committee, agreed "what matters most is preventing more serious forms of Covid-19" and that more extensive trials involving the South African strain were still needed. "It is by no means clear if it is more or less effective against the variant than other vaccines," he added. In Britain, Oxford University said Friday researchers had found its jab had "similar efficacy" against a more contagious variant that first emerged in September and has become the dominant form of coronavirus across the country. The news was welcomed in Britain, where some 113,000 people have died during the pandemic, and where vaccines are seen as a way out of the crisis. "We are ready to protect our most vulnerable and stay a step ahead of the virus, whatever it throws at us," vaccines minister Nadhim Zahawi wrote Monday in the Daily Telegraph.

London: The coronavirus vaccine developed in Britain by Oxford University and UK-Swedish pharmaceutical firm AstraZeneca has suffered several setbacks since its development, dampening hopes over its global role in ending the pandemic. Doubts have been heightened after South Africa suspended the start of its inoculation programme using the jab this week, following research it had failed to prevent mild and moderate cases of a virus variant there. The shot was already under scrutiny about its efficacy for over-65s, after several European countries restricted its use to younger adults only, despite approval from the EU medicines agency for all ages. In a sign of the mixed-messaging, French President Emmanuel Macron said at the end of January the vaccine was "quasi-ineffective for people over 65". Many poorer nations around the world are relying on the logistical advantages offered by the AstraZeneca-Oxford vaccine, which does not require ultra-low storage conditions. In Britain, where more than 12 million jabs have been given as part of the country's biggest ever vaccination drive, it has been administered alongside the Pfizer-BioNTech shot. Prime Minister Boris Johnson on Monday sought to reassure the millions of Britons already given the AstraZeneca-Oxford vaccine, telling reporters UK officials believe both jabs were "effective in combating serious disease and death against all variants". Scientists were getting "ever faster and more expert" to come up with "variants of the vaccines" to adapt to the evolving situation, he added. 'Minimal protection' The University of Witwatersrand, Johannesburg, which conducted the trial that has prompted the latest concerns, reported Sunday that it only "provides minimal protection against mild-moderate Covid-19 infection" from the South African variant. However, AstraZeneca noted none of the 2,000 participants developed serious symptoms and reiterated its belief that the vaccine will still protect against severe disease. Peter English, a former head of the British Medical Association's public health medicine committee, agreed "what matters most is preventing more serious forms of Covid-19" and that more extensive trials involving the South African strain were still needed. "It is by no means clear if it is more or less effective against the variant than other vaccines," he added. In Britain, Oxford University said Friday researchers had found its jab had "similar efficacy" against a more contagious variant that first emerged in September and has become the dominant form of coronavirus across the country. The news was welcomed in Britain, where some 113,000 people have died during the pandemic, and where vaccines are seen as a way out of the crisis. "We are ready to protect our most vulnerable and stay a step ahead of the virus, whatever it throws at us," vaccines minister Nadhim Zahawi wrote Monday in the Daily Telegraph.

London: The coronavirus vaccine developed in Britain by Oxford University and UK-Swedish pharmaceutical firm AstraZeneca has suffered several setbacks since its development, dampening hopes over its global role in ending the pandemic. Doubts have been heightened after South Africa suspended the start of its inoculation programme using the jab this week, following research it had failed to prevent mild and moderate cases of a virus variant there. The shot was already under scrutiny about its efficacy for over-65s, after several European countries restricted its use to younger adults only, despite approval from the EU medicines agency for all ages. In a sign of the mixed-messaging, French President Emmanuel Macron said at the end of January the vaccine was "quasi-ineffective for people over 65". Many poorer nations around the world are relying on the logistical advantages offered by the AstraZeneca-Oxford vaccine, which does not require ultra-low storage conditions. In Britain, where more than 12 million jabs have been given as part of the country's biggest ever vaccination drive, it has been administered alongside the Pfizer-BioNTech shot. Prime Minister Boris Johnson on Monday sought to reassure the millions of Britons already given the AstraZeneca-Oxford vaccine, telling reporters UK officials believe both jabs were "effective in combating serious disease and death against all variants". Scientists were getting "ever faster and more expert" to come up with "variants of the vaccines" to adapt to the evolving situation, he added. 'Minimal protection' The University of Witwatersrand, Johannesburg, which conducted the trial that has prompted the latest concerns, reported Sunday that it only "provides minimal protection against mild-moderate Covid-19 infection" from the South African variant. However, AstraZeneca noted none of the 2,000 participants developed serious symptoms and reiterated its belief that the vaccine will still protect against severe disease. Peter English, a former head of the British Medical Association's public health medicine committee, agreed "what matters most is preventing more serious forms of Covid-19" and that more extensive trials involving the South African strain were still needed. "It is by no means clear if it is more or less effective against the variant than other vaccines," he added. In Britain, Oxford University said Friday researchers had found its jab had "similar efficacy" against a more contagious variant that first emerged in September and has become the dominant form of coronavirus across the country. The news was welcomed in Britain, where some 113,000 people have died during the pandemic, and where vaccines are seen as a way out of the crisis. "We are ready to protect our most vulnerable and stay a step ahead of the virus, whatever it throws at us," vaccines minister Nadhim Zahawi wrote Monday in the Daily Telegraph.

https://canvas.oli.cmu.edu/eportfolios/92/Home/Raised_License_Plate_Frame__How_To_Get_The_Best_Possible_Ones

Category : business

Your Article Needs To Be Filled With Information, Not Fluff

Your Article Needs To Be Filled With Information, Not Fluff

- harder to make a deal and convince someone you deserve a better price on a vehicle if you are draped in expensive clothing. While you want to appear neat and ct


Single Pair Ethernet Market - Industry Analysis, size, Share and Upcoming Trends

Single Pair Ethernet Market - Industry Analysis, size, Share and Upcoming Trends

- Single Pair Ethernet Market is expected to exceed the market valuation of more than US$ XX million by 2027 expanding at a reasonable CAGR of around XX%


A Guide On The Subject Of Facebook Marketing

A Guide On The Subject Of Facebook Marketing

- harder to make a deal and convince someone you deserve a better price on a vehicle if you are draped in expensive clothing. While you want to appear neat an ct


Boost Up Your Career Opportunities With Salesforce CPQ-211 Certification

Boost Up Your Career Opportunities With Salesforce CPQ-211 Certification

- Proper in advance of you toss your funds concerning the counter and buy your subsequent substantial and expensive core textbook, consult with